New hope for hard-to-treat cancers: experimental drug PEP08 targets MTAP-deleted tumors
Disease control
Recruiting now
This early-phase study tests a new drug called PEP08 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 40 adults will receive PEP08 alone or w…
Phase: PHASE1 • Sponsor: PharmaEngine • Aim: Disease control
Last updated Jun 11, 2026 12:11 UTC